JP7765835B2 - 抗ＳＡＲＳ－ＣｏＶ－２薬 - Google Patents

抗ＳＡＲＳ－ＣｏＶ－２薬

Info

Publication number
JP7765835B2
JP7765835B2 JP2022524462A JP2022524462A JP7765835B2 JP 7765835 B2 JP7765835 B2 JP 7765835B2 JP 2022524462 A JP2022524462 A JP 2022524462A JP 2022524462 A JP2022524462 A JP 2022524462A JP 7765835 B2 JP7765835 B2 JP 7765835B2
Authority
JP
Japan
Prior art keywords
cycloalkyl
alkyl
cycloalkenyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524462A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021235392A1 (https=
Inventor
昌範 馬場
実佳 岡本
政明 外山
祐一 橋本
宏正 橋本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolys Biopharma Inc
Original Assignee
Oncolys Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolys Biopharma Inc filed Critical Oncolys Biopharma Inc
Publication of JPWO2021235392A1 publication Critical patent/JPWO2021235392A1/ja
Application granted granted Critical
Publication of JP7765835B2 publication Critical patent/JP7765835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022524462A 2020-05-18 2021-05-17 抗ＳＡＲＳ－ＣｏＶ－２薬 Active JP7765835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020086517 2020-05-18
JP2020086517 2020-05-18
PCT/JP2021/018617 WO2021235392A1 (ja) 2020-05-18 2021-05-17 抗ＳＡＲＳ－ＣｏＶ－２薬

Publications (2)

Publication Number Publication Date
JPWO2021235392A1 JPWO2021235392A1 (https=) 2021-11-25
JP7765835B2 true JP7765835B2 (ja) 2025-11-07

Family

ID=78708496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524462A Active JP7765835B2 (ja) 2020-05-18 2021-05-17 抗ＳＡＲＳ－ＣｏＶ－２薬

Country Status (4)

Country Link
US (1) US20230192622A1 (https=)
EP (1) EP4154884A4 (https=)
JP (1) JP7765835B2 (https=)
WO (1) WO2021235392A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023085432A1 (https=) * 2021-11-15 2023-05-19
WO2024237331A1 (ja) * 2023-05-17 2024-11-21 オンコリスバイオファーマ株式会社 フェナントリジノン誘導体のコリン塩

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093483A1 (ja) 2010-02-01 2011-08-04 国立大学法人鹿児島大学 C型肝炎治療剤
CN110960532A (zh) 2020-02-21 2020-04-07 金晓飞 一种抗冠状病毒的博落回苄基异喹啉类生物碱与白藜芦醇组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020086517A (ja) 2018-11-15 2020-06-04 キヤノン株式会社 情報処理装置及びその制御方法とプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093483A1 (ja) 2010-02-01 2011-08-04 国立大学法人鹿児島大学 C型肝炎治療剤
CN110960532A (zh) 2020-02-21 2020-04-07 金晓飞 一种抗冠状病毒的博落回苄基异喹啉类生物碱与白藜芦醇组合物及其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AOYAMA, Hiroshi et al.，Fused heterocyclic amido compounds as anti-hepatitis C virus agents，Bioorganic & Medicinal Chemistry，2011年，Vol.19, No.8，pp.2675-2687，ISSN 0968-0896
LIN, Shing-Yen et al.，Structural Basis for the Identification of the N-Terminal Domain of Coronavirus Nucleocapsid Protein，Journal of Medicinal Chemistry，2014年，Vol.57, No.6，pp.2247-2257，ISSN 0022-2623
NISHIYAMA, Yuko et al.，Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton，ACS Medicinal Chemistry Letters，2018年，Vol.9, No.7，pp.641-645，ISSN 1948-5875
NISHIYAMA, Yuko et al.，Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor，Bioorganic & Medicinal Chemistry，2014年，Vol.22, No.9，pp.2799-2808，ISSN 0968-0896
RASOOL, Nouman et al.，Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a comp，Structural Chemistry，2020年05月01日，Vol.31, No.5，pp.1777-1783，ISSN 1040-0400
ZUMLA, Alimuddin et al.，Coronaviruses-drug discovery and therapeutic options，Nature Reviews Drug Discovery，2016年，Vol.15, No.5，pp.327-347，ISSN 1474-1776

Also Published As

Publication number Publication date
JPWO2021235392A1 (https=) 2021-11-25
EP4154884A1 (en) 2023-03-29
EP4154884A4 (en) 2024-05-29
US20230192622A1 (en) 2023-06-22
WO2021235392A1 (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
US11638713B2 (en) Patentiflorin A analogs as antiviral agents
WO2018030463A1 (ja) 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物
KR20180080320A (ko) 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약
CN101247807A (zh) 噻唑化合物及使用方法
CN116120342B (zh) 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
JP7765835B2 (ja) 抗ＳＡＲＳ－ＣｏＶ－２薬
CN112521386B (zh) 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途
TW201002688A (en) Pharmaceutical compounds
JP6129471B2 (ja) （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の製造方法
RU2436786C1 (ru) Замещенные индолы, противовирусный активный компонент, способ получения и применения
TW200306192A (en) Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
CN116253719B (zh) 一种雌激素和雄激素受体双重降解剂及其应用
WO2023085432A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２薬
JP7603320B2 (ja) 環内チアミジノアミド－アリールアミド系化合物及びｂ型肝炎を治療するためのその使用
EP4255431A1 (en) Solid forms of emetine
CN102688234B (zh) 吲哚酮衍生物作为rsk2抑制剂的合成与应用
CN102633796B (zh) 一种苦参酸类衍生物的制备方法
KR20110074574A (ko) 1-부틸-2-히드록시아르알킬 피페라진 유도체 및 항-우울증제로서의 그 용도
CN111670191B (zh) 吡啶酮衍生物的晶型及制备方法和应用
CN113024557B (zh) 一种Peganumine A生物碱结构简化物及其应用
CN116041324A (zh) 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途
CN114805375B (zh) 一种n-苯基烷氧基二苯并吖庚因类化合物、其制备方法及医药用途
CN115197164B (zh) 新型噻唑类化合物及其制备方法和用途
WO2024237331A1 (ja) フェナントリジノン誘導体のコリン塩

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251020

R150 Certificate of patent or registration of utility model

Ref document number: 7765835

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150